Sequus regulatory update

Italy approved SEQU's Amphotec liposomal amphotericin B to treat severe systemic and/or deep mycoses in patients for whom conventional amphotericin B therapy cannot be used effectively due to toxicity or impaired renal function, or for patients who have failed conventional systemic antifungal therapy. ...